Tag: Uromune

Studies have shown that the Uromune vaccine (MV140) can significantly reduce the number of recurrent urinary tract infections (UTIs) for many patients, with some showing long-term benefits. While effective, the process to get Uromune vaccine is not straightforward and depends heavily on your geographic location and a specialist's prescription, as it is not commercially available in all regions.

According to the European Association of Urology, a long-term follow-up study showed that 54% of participants with recurrent UTIs remained infection-free for up to nine years after vaccination with Uromune. For those wondering where can I get Uromune, the answer depends heavily on geographical location, as this promising treatment is not universally approved or available.

Approximately 25–30% of women who experience one urinary tract infection (UTI) will have a recurrence, and for those suffering from chronic infections, the quest for an effective preventative treatment is crucial. The sublingual vaccine Uromune (MV140) has shown promise in reducing the frequency of recurrent UTIs and decreasing antibiotic usage, but how to order Uromune requires navigating specific international and regulatory pathways.

Recurrent urinary tract infections (rUTIs) are common, with an estimated 30% to 44% of women experiencing a second UTI within six months of the first [1.8.1]. This article explores a key question for many sufferers: Why is Uromune not available in the US as a treatment option?

Recurrent urinary tract infections (rUTIs) are a significant burden, affecting millions globally. This has driven demand for non-antibiotic solutions like the sublingual vaccine MV140 (Uromune), leading many to ask: is the MV140 available in the US? Currently, the answer is no, as it has not yet received approval from the U.S. Food and Drug Administration (FDA).